Evidence map›Paper›PMID 40454393›Full record

ArticleBlood neoplasia2024

CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib.

Chung Hoow Kok, Yazad Irani, Jade Clarson, Verity Saunders, Phuong Dang, Naranie Shanmuganathan, Susan Branford, David Yeung, Agnes S M Yong, Timothy P Hughes

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chung Hoow KokPrecision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, Australia.
Yazad IraniPrecision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, Australia.
Jade ClarsonPrecision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, Australia.
Verity SaundersPrecision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, Australia.
Phuong DangPrecision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, Australia.
Naranie ShanmuganathanPrecision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, Australia.
Susan BranfordAdelaide Medical School, University of Adelaide, Adelaide, Australia.
David YeungPrecision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, Australia.
Agnes S M YongPrecision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, Australia.
Timothy P HughesPrecision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Achieving a deep molecular response (DMR) is a prerequisite for treatment-free remission in chronic myeloid leukemia (CML) and a key milestone for patients with CML. This study identified patients unlikely to achieve a 5-year DMR through differential expression of cluster of differentiation (CD) genes, and clinical variables at diagnosis. Peripheral blood samples (n = 131) from patients treated with imatinib or nilotinib underwent transcriptomic microarray profiling. The decision-tree analysis delineated 2 distinct poor-risk (PR) cohorts, distinguished by high 3-month

Identifiers

PMID40454393
PMCPMC12082111

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.